US OptionsDetailed Quotes
NTLA241220C30000
- 0.10
- +0.05+100.00%
15min DelayClose Dec 2 16:00 ET
0.10High0.10Low
0.10Open0.05Pre Close20 Volume136 Open Interest30.00Strike Price200.00Turnover160.71%IV91.35%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.0491Delta0.0184Gamma157.30Leverage Ratio-0.0156Theta0.0003Rho7.73Eff Leverage0.0035Vega
Intellia Therapeutics Stock Discussion
Sign in to post a comment
Cathie Wood has been busy this week. The Ark Invest co-founder, CEO, and ace stock picker added to five of her existing growth stocks on Wednesday. I covered two of those names yesterday. Let's dive into the other three purchases.
What's she buying now? Some of the names on her Wednesday shopping list included Advanced Micro Devices $Advanced Micro Devices (AMD.US)$ , Pinterest $Pinterest (PINS.US)$ , and Intellia Therapeutics $Intellia Therapeutics (NTLA.US)$ . Let's t...
What's she buying now? Some of the names on her Wednesday shopping list included Advanced Micro Devices $Advanced Micro Devices (AMD.US)$ , Pinterest $Pinterest (PINS.US)$ , and Intellia Therapeutics $Intellia Therapeutics (NTLA.US)$ . Let's t...
15
3
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
7
2
If you had invested $10,000 in Cathie Wood's $ARK Innovation ETF (ARKK.US)$ and Warren Buffett's Berkshire Hathaway $Berkshire Hathaway-B (BRK.B.US)$ at different time frames here's how much you'd have today.
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
When $ARKK launched in 2014
Total Returns:
$BRK.B $28.6K
$ARKK $27.4K
5 years ago
Total Returns:
$BRK.B $19.7K
$ARKK $11.7K
3 years ago
Total Returns:
$BRK.B $16.4K
$ARKK $3.3K
1 year ago
Total Returns:
$BRK.B $12.8K
$ARKK $12.4K
At the start of 2024
Total Returns:
$BR...
+3
2
$Warren Buffett Portfolio (LIST2999.US)$ $Berkshire Hathaway-A (BRK.A.US)$ $Berkshire Hathaway-B (BRK.B.US)$ $ARK Innovation ETF (ARKK.US)$ $Coinbase (COIN.US)$ $Apple (AAPL.US)$ $Bank of America (BAC.US)$ $American Express (AXP.US)$ $S&P 500 Index (.SPX.US)$ $CRISPR Therapeutics (CRSP.US)$ $Intellia Therapeutics (NTLA.US)$
2
2
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Insiders selling shares at low prices may signal expected stock weakness. The absence of insider buying and increased selling over the past year suggest the shares aren't cheap, making the company a cautious investment.
1
Columns Gene Editing: Is This "Turning Point in Medicine" a Potential Source of Blockbuster Revenue?
The first treatment based on CRISPR technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
19
2
17
The future prospects of the company following disappointing price downfall despite revenue growth are now crucial. Long-term investors, however, made a 6% return each year if invested over five years, suggesting previous over-hype.
1
No comment yet
三和巴菲特 : Have you cried today? Baby
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 :
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 : Laughed.
71179109 : Intellia - 20% yesterday